Pioglitazone — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

5 Recruiting

6 Completed trials

11 Sponsors

12 Countries

Phase III

Phase II

Phase IV

Phase III: 4 Phase II: 6 Phase IV: 3

Indications tested

Diabetes mellitus 1 Vitiligo 1 Type 2 diabetes mellitus 1 Polycystic ovarian syndrome 1

Sponsors using this IMP

Centre Hospitalier Regional De Marseille 2 I.F.O. Istituti Fisioterapici Ospitalieri 2 Assistance Publique Hopitaux De Paris 1 Celltrion Inc. 1 Consorcio Centro De Investigacion Biomedica En Red 1 Eli Lilly Cork Limited 1 Fundacio Sant Joan De Deu 1 Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA 1 Karolinska University Hospital 1 Novo Nordisk A/S 1 Universita Cattolica Del Sacro Cuore 1

All trials

13 total

A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vi… Not authorised

2024-515642-17-00 Phase II 1 country I.F.O. Istituti Fisioterapici Ospitalieri
“A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental v… Pending

2025-523266-24-00 Phase II 1 country I.F.O. Istituti Fisioterapici Ospitalieri
CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P… Recruiting

2024-516328-32-00 Phase II 1 country Centre Hospitalier De Versailles
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes: A Randomized Open Intervention Study That Compares Empagliflozin, Pioglitazone… Recruiting

2024-513416-98-00 Phase II 2 countries Karolinska University Hospital
SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy Recruiting

2025-521748-39-00 Phase IV 1 country Universita Cattolica Del Sacro Cuore
PROMETEO-HG Recruiting

2024-516561-37-01 Phase III 1 country Consorcio Centro De Investigacion Biomedica En Red
A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATO Recruiting

2022-501057-36-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Clinical trial to evaluate whether personalized treatment based on genetics improves type 2 diabetes control Ended

2025-520686-46-00 Phase IV 1 country Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospita…
PIO2STOP_Combination study of Pioglitazone and Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia patients after failure of a TKI… Ended

2024-515460-31-00 Phase II 1 country Centre Hospitalier De Versailles
Clinical study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient gly… Ended

2023-508924-36-00 Phase III 1 country Celltrion Inc.
A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar… Ended

2022-502484-38-00 Phase III 3 countries Novo Nordisk A/S
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended

2022-500101-41-00 Phase IV 4 countries Eli Lilly Cork Limited
A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose comb… Ended

2024-518527-29-00 Phase II 5 countries Fundacio Sant Joan De Deu

Showing 1–13 of 13 trials

← All drugs A–Z